Impact of Tumor Site and Adjuvant Radiotherapy on Survival of Patients with Adenoid Cystic Carcinoma: A SEER Database Analysis.
Impact of Tumor Site and Adjuvant Radiotherapy on Survival of Patients with Adenoid Cystic Carcinoma: A SEER Database Analysis.
复制标题
DOI：
10.3390/cancers13040589
复制
发表时间：
2021-02-03
期刊：
影响因子：
5.2
通讯作者：
Amelio AL
中科院分区：
文献类型：
--
作者：
Tasoulas J;Divaris K;Theocharis S;Farquhar D;Shen C;Hackman T;Amelio AL
腺样囊性癌是一种罕见但致命的涎腺肿瘤，占头颈部肿瘤的不到1%。它可以影响头颈部的几个部位，但肿瘤部位对生存和治疗反应的潜在作用仍不清楚，迄今为止，肿瘤位置在治疗计划和生存中的作用尚未被考虑。我们试图通过对监测、流行病学和最终结果（SEER）数据库的分析来解决这些知识缺口。我们的分析发现，与其他部位相比，颌下腺腺样囊性癌患者，特别是晚期疾病患者的生存率较差，并且从辅助放疗中受益最大。与此相反，早期和非颌下腺样囊性癌患者显示，辅助放疗（aRT）没有生存的好处。这些结果强调了肿瘤部位对头颈部ACC患者的治疗反应和生存的作用。腺样囊性癌（ACC）是一种罕见的涎腺肿瘤，表现出侵袭性行为，经常复发和转移。关于临床病理学参数和辅助放疗（aRT）对ACC疾病特异性（DSS）和总生存期（OS）的影响的信息很少。我们从监测、流行病学和最终结果（SEER）数据库中提取了1439例患有严重或轻微口内唾液腺ACC的患者的人口统计学、治疗和生存信息。使用风险比（HR）和95%置信区间（CI）估计肿瘤特征和aRT与OS和DSS之间的相关性。下颌下腺ACC的预后最差（与腮腺相比，调整后的DSS HR = 1.48; 95% CI = 0.99-2.20），并且这种差异在晚期肿瘤患者中更为明显（调整后的DSS HR = 1.93; 95% CI = 1.13-3.30）。aRT仅在III期颌下ACC患者中与总生存率增加相关（HR = 0.64; 95%CI = 0.42-0.98），在任何其他组中均无获益。总之，下颌下腺ACC的预后比其他腺体亚部位差，可能受益于aRT。下颌下腺和其他主要或次要腺体ACC之间的不同结果需要进一步的机制研究。
Adenoid cystic carcinoma (ACC) is a rare but lethal salivary gland tumor, comprising less than 1% of head and neck neoplasms. It can affect several sites in the head and neck region, but the potential role of tumor site on survival and treatment response remains unclear and, to this day, the role that tumor location plays in treatment planning and survival has not been considered. We sought to address these knowledge gaps via analyses of the Surveillance, Epidemiology, and End Results (SEER) database. Our analysis identified that patients with submandibular gland adenoid cystic carcinomas, particularly those with late-stage disease, had worse survival compared to other sites and benefited the most from adjuvant radiotherapy. In contrast, early-stage and non-submandibular adenoid cystic carcinoma patients showed no survival benefit from adjuvant radiotherapy (aRT). These results underscore the role of tumor site on treatment response and survival of patients with head and neck ACC. Adenoid cystic carcinoma (ACC) is a rare salivary gland tumor, displaying aggressive behavior with frequent recurrence and metastasis. Little information exists regarding the impact of clinicopathological parameters and adjuvant radiotherapy (aRT) on ACC disease specific (DSS) and overall survival (OS). We extracted demographic, treatment, and survival information of 1439 patients with major or minor intraoral salivary gland ACC from the Surveillance, Epidemiology, and End Results (SEER) database. The associations between tumor characteristics and aRT with OS and DSS were estimated using hazard ratios (HR) and 95% confidence intervals (CI). Submandibular gland ACCs had the worst prognosis (adjusted DSS HR = 1.48; 95% CI = 0.99–2.20, compared to parotid), and this difference was more pronounced among patients with advanced-stage tumors (adjusted DSS HR = 1.93; 95% CI = 1.13–3.30). aRT was associated with increased overall survival only among stage III submandibular ACC patients (HR = 0.64; 95% CI = 0.42–0.98) and had no benefit in any other group. In conclusion, submandibular gland ACC carries a worse prognosis than other gland subsites and may benefit from aRT. The different outcomes between submandibular gland and other major or minor gland ACCs warrant further mechanistic investigation.
登录
查看更多内容
影响因子：
--
作者：
Frerich CA;Brayer KJ;Painter BM;Kang H;Mitani Y;El-Naggar AK;Ness SA
通讯作者：
Ness SA
影响因子：
3.7
作者：
Bilimoria KY;Stewart AK;Winchester DP;Ko CY
通讯作者：
Ko CY
DOI：
10.1016/0360-3016(95)00122-f
发表时间：
1995-06-15
影响因子：
7
作者：
GARDEN, AS;WEBER, RS;PETERS, LJ
通讯作者：
PETERS, LJ
DOI：
10.1002/hed.24740
发表时间：
2017-05-01
影响因子：
2.9
作者：
Amit, Moran;Na'ara, Shorook;Gil, Ziv
通讯作者：
Gil, Ziv
影响因子：
2.5
作者：
Roh, Jong-Lyel;Choi, Seung-Ho;Kim, Sang Yoon
通讯作者：
Kim, Sang Yoon